COVID-19 Vaccine Pipeline Market Size, Share, Growth Report 2032

Global COVID-19 Vaccine Pipeline Market: Overview

Covid-19 is a contagious disease that is caused due to the novel Coronavirus. The spread of COVID-19 started across Wuhan, China in the month of December, 2019. WHO (World Health Organization) announced COVID-19 outbreak as a pandemic on 11 March 2020. COVID-19 cases have been expanding globally with almost every nation being affected with remarkable number of cases and deaths because of the pandemic. Until now, the United States has recorded over 10.62 million total cases, with about 6.4 million active cases, and more than 300,000 deaths, hence making it the worst affected country. The Europe has recorded about 20 million confirmed cases, with Russia having recorded 2.5 million cases, followed by France’s 2.3 million count.

The virus that gives rise to COVID-19 is passed via droplets when an infected person exhales, coughs, or sneezes. The droplets are quite heavy to stay in the air and fall to ground quickly. One transmits infection to someone when he gets within close range of a person or a group of people, or the virus can also be transferred by touching an area or surface which is infected due to the virus, and then using the same unwashed hands to eat, or to even touch one’s mouth, nose, or eyes. The most common indications of COVID-19 are dry cough, aches & pains, tiredness, fever, sore throat, a rash on skin, or discoloration of fingers or toes.

Global COVID-19 Vaccine Pipeline Market: Growth Factors

As of now, no particular cure or treatment has been developed to treat COVID-19. However, a number of R&D projects are being conducted by multiple prominent companies working in biopharmaceutical market in the hope of creating a vaccine for COVID-19 that will permanently immunize a person against it. This is a major growth factor pushing the growth of the global COVID-19 vaccine pipeline market.

The WHO is focusing on accelerating the efforts for the development of a COVID-19 vaccine on the most expansive scale. Healthcare professionals have predicted that the development procedure of the COVID-19 vaccine may take about 12 to 18 months to reach the common public.

However, it is difficult to say whether these COVID-19 vaccines will give permanent immunization against the virus. This factor could potentially hamper the growth of the global COVID-19 vaccine pipeline market size. Studies and researches are still going on to find out if a vaccine would be an indefinite cure. Nonetheless, there is good news that some of the studies show that a majority of earlier affected people who overcame the virus naturally develop immunity against the virus, and this helps the person not to get infected again. However, the doctors and researchers are still making sure if herd immunity and other such theories are valid, and if they have a scientific background.

Global COVID-19 Vaccine Pipeline Market: Segmentation

The global COVID-19 vaccine pipeline market can be segmented by end-user, type of vaccine, and regions. By type, the market can be bifurcated into live attenuated virus vaccine, viral vector vaccine, inactivated or killed virus, virus-like particle vaccine, subunit vaccine, RNA vaccine, and DNA vaccine. Hospitals, commercial or private laboratories, and public health laboratories can be the key end-user segments of the global COVID-19 vaccine pipeline market.

Global COVID-19 Vaccine Pipeline Market: Regional Analysis

North America is set to garner substantial pace over the upcoming times, driven by the growing bulk of investments in the research initiatives and the presence of numerous candidates pursuing regulatory approvals as well as seeking commercialization, boosting the global COVID-19 vaccine pipeline market share.

Asia Pacific has been promising considerable opportunities as well, driven by the availability of necessary chemicals and raw materials in massive quantities. The rise in government funding across the healthcare sector in the region has also been triggering the expansion of the global COVID-19 vaccine pipeline market. The growing number of medical breakthroughs and the presence of leading manufacturers of drugs and vaccines in the countries located in Asia Pacific are also fueling further development.

For instance, Taiwan-based Abnova Corporation has emerged as the world’s largest manufacturer of antibodies, and has been developing a RNA-based vaccine against SARS-CoV-2. India is likely to emerge as a prime contributor in the global COVID-19 vaccine pipeline market share, due to its three candidates being in phase 2/3 of the human trials and four more players to begin late-stage trials toward the end of the year, according to the WHO data.

Global COVID-19 Vaccine Pipeline Market: Competitive Players

Some of the market players operating in the global COVID-19 vaccine pipeline market include Tonix Pharmaceuticals, Merck & Co., Novartis, Cipla, Sorrento Therapeutics, AstraZeneca, CSL Limited., Sanofi, GlaxoSmithKline, Serum Institute of India, Lupin, Biopin, Dr. Reddy’s Laboratories, Cadila Healthcare, Sun Pharmaceutical Industries, Hetero Drugs, and Alkem Laboratories.

Global COVID-19 Vaccine Pipeline Market: Regional Segment Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

What Reports Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.